<?xml version="1.0" encoding="UTF-8"?>
<ref id="B126-molecules-25-03846">
 <label>126.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Bisson</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>McAlpine</surname>
    <given-names>J.B.</given-names>
   </name>
   <name>
    <surname>Friesen</surname>
    <given-names>J.B.</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>S.-N.</given-names>
   </name>
   <name>
    <surname>Graham</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Pauli</surname>
    <given-names>G.F.</given-names>
   </name>
  </person-group>
  <article-title>Can Invalid Bioactives Undermine Natural Product-Based Drug Discovery?</article-title>
  <source>J. Med. Chem.</source>
  <year>2016</year>
  <volume>59</volume>
  <fpage>1671</fpage>
  <lpage>1690</lpage>
  <pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01009</pub-id>
  <pub-id pub-id-type="pmid">26505758</pub-id>
 </element-citation>
</ref>
